Nimustine Hydrochloride for Injection

1. Anti-tumor effect: (1) It shows high anti-tumor activity against mouse leukemia L-1210. (2) It has a wide anti-tumor spectrum against mouse transplanted tumors. It shows excellent effects on lymphocytic leukemia L1210, granulocytic leukemia C-1498, plasmacytoma X-5563 (ascites type), Ehrlich's ascites carcinoma, and dural sarcoma MS-147. (3) This agent has a life-extending effect on mice with lymphocytic leukemia L1210 and methylcholanthrene-induced malignant glioma cells transplanted into the brain. 2. Mechanism of action: The main mechanism of action is to alkylate intracellular DNA and reduce the molecular weight of DNA, thereby inhibiting DNA synthesis. Toxicology: 1. Acute toxicity: (1) LD50 value (mg/kg) When administered intravenously, the LD50 values of male and female mice are 65 and 59 mg/kg, respectively, and the LD50 values of male and female rats are 47.8 and 45.6 mg/kg, respectively. (2) Effects on blood (2.5, 5, 10 mg/kg intravenous administration in dogs) The red blood cell count and reticulocyte count of the 2.5 mg/kg group decreased on the 7th to 11th day of administration, and basically returned to normal on the 14th to 16th day. There was no significant change in the platelet count. The white blood cell count decreased significantly until the 7th day, but then gradually increased and returned to normal on the 35th day. The eosinophil count also had a similar trend. The red blood cell count and platelet count of the 5 mg/kg and 10 mg/kg groups decreased significantly, and all died on the 10th to 17th day. 2. Subacute toxicity: (0.4, 2, 10 mg/kg/day intravenous administration for 4 weeks in rats) 0.4 mg/kg group: Female rats had mild leukopenia, but the organ weight, especially the actual weight, did not change in accordance with the body weight ratio. 2 mg/kg group: There was inhibition of weight gain, atrophy of lymphatic system tissue and bone marrow, and leukopenia. 10mg/kg group: Death due to systemic bleeding tendency occurred (dogs were intravenously administered at 0.08, 0.2, 0.5mg/kg/day for 5 weeks). 3. Teratogenicity test (rat 0.05, 0.1, 0.5mg/kg/day, gestational day 7-17, intravenous administration) In late pregnancy, the average birth weight of the 0.5mg/kg group was reduced, and the group with more than 0.1mg/kg had polydactyly and other appearance abnormalities, which was teratogenic.

Nimustine hydrochloride

This product is a light yellow powder, odorless, easily soluble in methanol, and difficult to dissolve in glacial acetic acid.

Relieve the subjective symptoms and signs of the following diseases: brain and neck cancer, brain tumors, lung cancer, digestive tract cancer (gastric cancer, colon/rectum cancer, esophageal cancer), malignant lymphoma and leukemia, etc.

Common dosage: 2-3 mg/kg body weight/time, dissolved in water for injection (5 mg/ml), intravenous injection. Then stop the drug for 4-6 weeks according to the peripheral blood picture, or 2 mg/kg body weight/time, intravenous administration, give it once every week, and then stop the drug for 4-6 weeks according to the peripheral blood picture after 2-3 weeks. This product should be used immediately after being prepared into solution.

Symptoms such as leukopenia, thrombocytopenia, anemia, bleeding tendency, allergies, loss of appetite, nausea, fatigue, fever, headache, hair loss and hypoproteinemia may be seen, and occasionally the liver and kidney functions may be slightly affected and interstitial pneumonia may occur.

3. The following patients should use the drug with caution: (1) Patients with impaired liver function. (2) Patients with impaired kidney function. (3) Patients with concurrent infections. (4) Patients with water beans (sometimes fatal systemic disorders occur). 4. Side effects: Please refer to relevant medical information for details.

When used in combination with other anti-tumor drugs or radioactive rays, bone marrow suppression may sometimes be aggravated.

Store in a cool, dark place away from light.

25mg

Hainan Tongyong Kangli Pharmaceutical Co., Ltd.

• Founded in:

  2000-05-16

• Address:

  Room 221-226, Building 1, No. 269, Nanhai Avenue, National High-tech Industrial Development Zone, Haikou City, Hainan Province

• Tax NO.:

  914600007212236930

• Registered Funds:

  50 million yuan

• Email:

  Log in to view